Mirum Pharmaceuticals, Inc. (MIRM) Fair Value 2026

MIRM · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.9 /10

32 fundamental signals · 6 models active

Value Trap Risk

LOW (28/100)

Quick Summary — As of 2026-08-28, Mirum Pharmaceuticals, Inc. (MIRM) trades at $97.46, versus a $7.07 median fair value across its 6 active models — 92.7% below the current price. QOC: 5.9/10. Value Trap Risk: 28/100 (LOW). 6/13 models active. Within that set, the Bayesian DCF component alone returns $22.27.

Key Facts

Ticker
MIRM
Price
$97.46
Quality Score
5.9/10
Value Trap Risk
28/100
Models Active
6/13
Last Updated
Strength: 6 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Mirum Pharmaceuticals, Inc. (MIRM) Undervalued or Overvalued in 2026?

According to CirclFi’s 6-model valuation engine, Mirum Pharmaceuticals, Inc. (MIRM) appears overvalued as of : the median of 6 independent fair value estimates is $7.07, 92.7% below the current price of $97.46. Estimates range from $2.07 to $22.27. MIRM scores 5.9/10 on fundamental quality and 28/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. MIRM’s -92.7% gap is wider than that market norm, and the Biotechnology sector median is -64.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Mirum Pharmaceuticals, Inc. Stock in 2026? →

What Fair Value Does Each Model Give MIRM?

6 Intrinsic Value Models vs. Current Price ($97.46)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $22.27 -77.2%
Ensemble · Low Conviction
 $8.19 -91.6%
Scenario · High Conviction
 $2.07 -97.9%
Unlock the Full Matrix

Access 3 additional models including Sentiment SOTP, FTNN Topology, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 6 Models →

Cancel anytime · No contracts · Instant access

What Is MIRM's Fair Value Range?

Spread across 6 independent models · $2.07 to $22.27

CirclFi's 6 active models place Mirum Pharmaceuticals, Inc. (MIRM) between $2.07 and $22.27 per share, a spread of 286% of the median. The median of that range — $7.07 — is the fair value CirclFi publishes for MIRM, against a current price of $97.46.

Low · First ChicagoHigh · Bayesian DCF
$2.07median $7.07$22.27
Where the range comes from
Most bearish modelFirst Chicago$2.07
Most bullish modelBayesian DCF$22.27
Model agreement0 bullish · 6 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for MIRM. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on MIRM, not a CirclFi price target. How each model works →

What Is Mirum Pharmaceuticals, Inc. (MIRM) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Mirum Pharmaceuticals, Inc.'s intrinsic value is estimated at $7.07, suggesting the stock is overvalued at its current price of $97.46. With 6 out of 6 models flagging downside (-92.7% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About MIRM?

6 of 13 models are currently active for MIRM. All 6 active models suggest the stock trades above fair value. Taken together, their median fair value for MIRM is $7.07 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $22.27 on its own, implying -77.2% downside from the current price. See which stocks rank higher →

How Does MIRM Rank in Biotechnology?

Among 625 Biotechnology stocks, MIRM ranks #162 by Quality of Company score. CirclFi's QOC score of 5.9/10 evaluates 32 fundamental signals. A score of 5.9 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a biotech sector, Mirum Pharmaceuticals, Inc. operates in a sector where partnership revenue is a critical driver of valuation. Investors evaluating MIRM should weigh these sector-specific dynamics alongside our model-derived fair values.

Is MIRM a Value Trap?

CirclFi's Value Trap algorithm assigns MIRM a score of 28/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

6 of 13 models are active for Mirum Pharmaceuticals, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Mirum Pharmaceuticals, Inc.'s fundamental quality profile registers 5.9/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

Models cluster within a tight range (+20.7% spread), increasing conviction. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every MIRM valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across MIRM's 6 active models, average confidence is 37%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Mirum Pharmaceuticals, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

BOLTBolt Biotherapeutics, Inc.QOC 5.9AURXNuo Therapeutics, Inc.QOC 5.9RLAYRelay Therapeutics, Inc.QOC 5.9TARSTarsus Pharmaceuticals, Inc.QOC 5.9OKUROnKure Therapeutics, Inc.QOC 5.9CELZCreative Medical Technology Holdings, Inc.QOC 5.9ZURAZura Bio LimitedQOC 5.0TECXTectonic Therapeutic, Inc.QOC 4.4AUPHAurinia Pharmaceuticals Inc.QOC 9.2EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: BOLT · AURX · RLAY · TARS · OKUR · CELZ · ZURA · TECX · AUPH · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to MIRM?

6 companies across all industries closest to MIRM’s Quality of Company score of 5.9/10.

CGTLCreative Global Technology Holdings LimitedQOC 5.9AMSAmerican Shared Hospital ServicesQOC 5.9GUERGuerrilla RF, Inc.QOC 5.9EPEmpire Petroleum CorporationQOC 5.9STKSThe ONE Group Hospitality, Inc.QOC 5.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: CGTL · AMS · GUER · EP · STKS · NVDA

Where Does MIRM Sit in CirclFi's Biotechnology Rankings?

MIRM is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Mirum Pharmaceuticals, Inc.’s Valuation?

What is Mirum Pharmaceuticals, Inc.'s intrinsic value in 2026?

CirclFi puts Mirum Pharmaceuticals, Inc. (MIRM)'s intrinsic value at $7.07 — the median of 6 independent model estimates as of 2026-08-28, ranging from $2.07 to $22.27. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $22.27 on its own. The Quality of Company score is 5.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is MIRM overvalued or undervalued right now?

At $97.46, 0 of 6 active models suggest MIRM may be undervalued, while 6 indicate potential overvaluation. The median of all 6 fair value estimates is $7.07, 92.7% below the current price of $97.46 — a consensus view that MIRM is overvalued. The assessment depends on which methodology best fits Mirum Pharmaceuticals, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.9 mean for MIRM?

Mirum Pharmaceuticals, Inc.'s QOC of 5.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on MIRM?

CirclFi analyzes MIRM with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 6 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on MIRM?

Of the 6 models currently active on MIRM, Bayesian DCF is the most bullish at $22.27 per share, and First Chicago is the most bearish at $2.07. CirclFi's published fair value for MIRM is the median of that range, $7.07, not either extreme. The gap between the two ends equals 286% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is MIRM a value trap in 2026?

Mirum Pharmaceuticals, Inc.'s Value Trap score is 28/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 6-model valuation engine, Mirum Pharmaceuticals, Inc. (MIRM) has a median fair value of $7.07 — 92.7% below the current price of $97.46 — as of 2026-08-28.” Source: circlfi.com/stock/MIRM/ · Methodology
Primary sources for this MIRM valuation
  • Financial statements: Mirum Pharmaceuticals, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001759425) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for MIRM as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 6 mathematical frameworks give you clarity on MIRM.

Unlock All 6 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

3 models hidden for MIRM Unlock All 6 — $39/mo